| Year |
Citation |
Score |
| 2013 |
Pustylnik S, Fiorino C, Nabavi N, Zappitelli T, da Silva R, Aubin JE, Harrison RE. EB1 levels are elevated in ascorbic Acid (AA)-stimulated osteoblasts and mediate cell-cell adhesion-induced osteoblast differentiation. The Journal of Biological Chemistry. 288: 22096-110. PMID 23740245 DOI: 10.1074/Jbc.M113.481515 |
0.673 |
|
| 2013 |
Durand M, Komarova SV, Bhargava A, Trebec-Reynolds DP, Li K, Fiorino C, Maria O, Nabavi N, Manolson MF, Harrison RE, Dixon SJ, Sims SM, Mizianty MJ, Kurgan L, Haroun S, et al. Monocytes from patients with osteoarthritis display increased osteoclastogenesis and bone resorption: the In Vitro Osteoclast Differentiation in Arthritis study. Arthritis and Rheumatism. 65: 148-58. PMID 23044761 DOI: 10.1002/Art.37722 |
0.649 |
|
| 2012 |
Nabavi N, Pustylnik S, Harrison RE. Rab GTPase mediated procollagen trafficking in ascorbic acid stimulated osteoblasts. Plos One. 7: e46265. PMID 23050002 DOI: 10.1371/Journal.Pone.0046265 |
0.656 |
|
| 2011 |
Nabavi N, Khandani A, Camirand A, Harrison RE. Effects of microgravity on osteoclast bone resorption and osteoblast cytoskeletal organization and adhesion. Bone. 49: 965-74. PMID 21839189 DOI: 10.1016/J.Bone.2011.07.036 |
0.652 |
|
| 2011 |
Durand M, Boire G, Komarova SV, Dixon SJ, Sims SM, Harrison RE, Nabavi N, Maria O, Manolson MF, Mizianty M, Kurgan L, de Brum-Fernandes AJ. The increased in vitro osteoclastogenesis in patients with rheumatoid arthritis is due to increased percentage of precursors and decreased apoptosis - the In Vitro Osteoclast Differentiation in Arthritis (IODA) study. Bone. 48: 588-96. PMID 20959150 DOI: 10.1016/J.Bone.2010.10.167 |
0.631 |
|
| 2010 |
Hassanzadeh A, Nitsche M, Armstrong S, Nabavi N, Harrison R, Dixon SJ, Langbein U, Mittler S. Optical waveguides formed by silver ion exchange in Schott SG11 glass for waveguide evanescent field fluorescence microscopy: evanescent images of HEK293 cells. Journal of Biomedical Optics. 15: 036018. PMID 20615020 DOI: 10.1117/1.3443796 |
0.557 |
|
| 2008 |
Nabavi N, Urukova Y, Cardelli M, Aubin JE, Harrison RE. Lysosome dispersion in osteoblasts accommodates enhanced collagen production during differentiation. The Journal of Biological Chemistry. 283: 19678-90. PMID 18463099 DOI: 10.1074/Jbc.M802517200 |
0.657 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2013 |
Shin J, He M, Liu Y, Paredes S, Villanova L, Brown K, Qiu X, Nabavi N, Mohrin M, Wojnoonski K, Li P, Cheng HL, Murphy A, Valenzuela D, Luo H, et al. Correction to SIRT7 Represses Myc Activity to Suppress ER Stress and Prevent Fatty Liver Disease. [Cell Reports 5, 7, (2013)] 654-665 Cell Reports. 5: 1479. DOI: 10.1016/J.Celrep.2013.11.036 |
0.276 |
|
| 2023 |
Sadrkhanloo M, Paskeh MDA, Hashemi M, Raesi R, Bahonar A, Nakhaee Z, Entezari M, Beig Goharrizi MAS, Salimimoghadam S, Ren J, Nabavi N, Rashidi M, Dehkhoda F, Taheriazam A, Tan SC, et al. New emerging targets in osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in carcinogenesis. Pathology, Research and Practice. 251: 154902. PMID 37922723 DOI: 10.1016/j.prp.2023.154902 |
0.235 |
|
| 2023 |
Baniasadi M, Talebi S, Mokhtari K, Zabolian AH, Khosroshahi EM, Entezari M, Dehkhoda F, Nabavi N, Hashemi M. Role of non-coding RNAs in osteoporosis. Pathology, Research and Practice. 253: 155036. PMID 38134836 DOI: 10.1016/j.prp.2023.155036 |
0.227 |
|
| 2013 |
Shin J, He M, Liu Y, Paredes S, Villanova L, Brown K, Qiu X, Nabavi N, Mohrin M, Wojnoonski K, Li P, Cheng HL, Murphy AJ, Valenzuela DM, Luo H, et al. SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Reports. 5: 654-65. PMID 24210820 DOI: 10.1016/J.Celrep.2013.10.007 |
0.225 |
|
| 2021 |
Mather RL, Parolia A, Carson SE, Venalainen E, Roig-Carles D, Jaber M, Chu SC, Alborelli I, Wu R, Lin D, Nabavi N, Jachetti E, Colombo MP, Xue H, Pucci P, et al. The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms. Molecular Oncology. PMID 33793068 DOI: 10.1002/1878-0261.12954 |
0.19 |
|
| 2023 |
Hashemi M, Razzazan M, Bagheri M, Asadi S, Jamali B, Khalafi M, Azimi A, Rad S, Behroozaghdam M, Nabavi N, Rashidi M, Dehkhoda F, Taheriazam A, Entezari M. Versatile function of AMPK signaling in osteosarcoma: An old player with new emerging carcinogenic functions. Pathology, Research and Practice. 251: 154849. PMID 37837858 DOI: 10.1016/j.prp.2023.154849 |
0.186 |
|
| 2021 |
Mirzaei S, Gholami MH, Mahabady MK, Nabavi N, Zabolian A, Banihashemi SM, Haddadi A, Entezari M, Hushmandi K, Makvandi P, Samarghandian S, Zarrabi A, Ashrafizadeh M, Khan H. Pre-clinical investigation of STAT3 pathway in bladder cancer: Paving the way for clinical translation. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 133: 111077. PMID 33378975 DOI: 10.1016/j.biopha.2020.111077 |
0.185 |
|
| 2018 |
Qu S, Xue H, Dong X, Lin D, Wu R, Nabavi N, Collins CC, Gleave ME, Gout PW, Wang Y. Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. International Journal of Cancer. PMID 29441566 DOI: 10.1002/ijc.31310 |
0.181 |
|
| 2024 |
Ebrahimi N, Manavi MS, Faghihkhorasani F, Fakhr SS, Baei FJ, Khorasani FF, Zare MM, Far NP, Rezaei-Tazangi F, Ren J, Reiter RJ, Nabavi N, Aref AR, Chen C, Ertas YN, et al. Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response. Cancer Metastasis Reviews. PMID 38227149 DOI: 10.1007/s10555-023-10162-7 |
0.175 |
|
| 2023 |
Hashemi M, Abbaszadeh S, Rashidi M, Amini N, Talebi Anaraki K, Motahhary M, Khalilipouya E, Harif Nashtifani A, Shafiei S, Ramezani Farani M, Nabavi N, Salimimoghadam S, Aref AR, Raesi R, Taheriazam A, et al. STAT3 as a newly emerging target in colorectal cancer therapy: Tumorigenesis, therapy response, and pharmacological/nanoplatform strategies. Environmental Research. 116458. PMID 37348629 DOI: 10.1016/j.envres.2023.116458 |
0.163 |
|
| 2018 |
Choi SYC, Ettinger SL, Lin D, Xue H, Ci X, Nabavi N, Bell RH, Mo F, Gout PW, Fleshner NE, Gleave ME, Collins CC, Wang Y. Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer. Cancer Medicine. PMID 29905005 DOI: 10.1002/cam4.1587 |
0.159 |
|
| 2023 |
Sabouni E, Nejad MM, Mojtabavi S, Khoshduz S, Mojtabavi M, Nadafzadeh N, Nikpanjeh N, Mirzaei S, Hashemi M, Aref AR, Khorrami R, Nabavi N, Ertas YN, Salimimoghadam S, Zandieh MA, et al. Unraveling the function of epithelial-mesenchymal transition (EMT) in colorectal cancer: Metastasis, therapy response, and revisiting molecular pathways. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 160: 114395. PMID 36804124 DOI: 10.1016/j.biopha.2023.114395 |
0.15 |
|
| 2021 |
Ashrafizaveh S, Ashrafizadeh M, Zarrabi A, Husmandi K, Zabolian A, Shahinozzaman M, Aref AR, Hamblin MR, Nabavi N, Crea F, Wang Y, Ahn KS. Long non-coding RNA in the doxorubicin resistance of cancer cells. Cancer Letters. PMID 33766750 DOI: 10.1016/j.canlet.2021.03.018 |
0.15 |
|
| 2023 |
Rezaei S, Nikpanjeh N, Rezaee A, Gholami S, Hashemipour R, Biavarz N, Yousefi F, Tashakori A, Salmani F, Rajabi R, Khorrami R, Nabavi N, Ren J, Salimimoghadam S, Rashidi M, et al. PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation. European Journal of Pharmacology. 175909. PMID 37490949 DOI: 10.1016/j.ejphar.2023.175909 |
0.148 |
|
| 2021 |
Oo HZ, Lohinai Z, Khazamipour N, Lo J, Kumar G, Pihl J, Adomat H, Nabavi N, Behmanesh H, Zhai B, Dagil R, Choudhary S, Gustavsson T, Clausen TM, Esko JD, et al. Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer. Cancers. 13. PMID 34503301 DOI: 10.3390/cancers13174489 |
0.139 |
|
| 2023 |
Hashemi M, Esbati N, Rashidi M, Gholami S, Raesi R, Bidoki SS, Goharrizi MASB, Motlagh YSM, Khorrami R, Tavakolpournegari A, Nabavi N, Zou R, Mohammadnahal L, Entezari M, Taheriazam A, et al. Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer. Translational Oncology. 40: 101846. PMID 38042134 DOI: 10.1016/j.tranon.2023.101846 |
0.139 |
|
| 2021 |
Mirzaei S, Mohammadi AT, Gholami MH, Hashemi F, Zarrabi A, Zabolian A, Hushmandi K, Makvandi P, Samec M, Liskova A, Kubatka P, Nabavi N, Aref AR, Ashrafizadeh M, Khan H, et al. Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance. Pharmacological Research. 105575. PMID 33771701 DOI: 10.1016/j.phrs.2021.105575 |
0.13 |
|
| 2023 |
Al-Rashidi RR, Noraldeen SAM, Kareem AK, Mahmoud AK, Kadhum WR, Ramírez-Coronel AA, Iswanto AH, Obaid RF, Jalil AT, Mustafa YF, Nabavi N, Wang Y, Wang L. Malignant function of nuclear factor-kappaB axis in prostate cancer: Molecular interactions and regulation by non-coding RNAs. Pharmacological Research. 106775. PMID 37075872 DOI: 10.1016/j.phrs.2023.106775 |
0.128 |
|
| 2023 |
Almajidi YQ, Kadhim MM, Alsaikhan F, Turki Jalil A, Hassan Sayyid N, Alexis Ramírez-Coronel A, Hassan Jawhar Z, Gupta J, Nabavi N, Yu W, Ertas YN. Doxorubicin-loaded micelles in tumor cell-specific chemotherapy. Environmental Research. 227: 115722. PMID 36948284 DOI: 10.1016/j.envres.2023.115722 |
0.127 |
|
| 2022 |
Mirzaei S, Gholami MH, Hushmandi K, Hshemi F, Zabolian A, Canadas I, Zarrabi A, Nabavi N, Aref AR, Crea F, Wang Y, Ashrafizadeh M, Kumar AP. The long and short non-coding RNAs modulating EZH2 signaling in cancer. Journal of Hematology & Oncology. 15: 18. PMID 35236381 DOI: 10.1186/s13045-022-01235-1 |
0.126 |
|
| 2022 |
Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, Hashemi M, Kalu A, Zarrabi A, Nabavi N, Rabiee N, Sharifi E, Karimi-Maleh H, Ashrafizadeh M, Kumar AP, Wang Y. Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. Journal of Experimental & Clinical Cancer Research : Cr. 41: 214. PMID 35773731 DOI: 10.1186/s13046-022-02406-1 |
0.123 |
|
| 2021 |
Ashrafizadeh M, Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Raei M, Hushmandi K, Zarrabi A, Voelcker NH, Aref AR, Hamblin MR, Varma RS, Samarghandian S, Arostegi IJ, Alzola M, ... ... Nabavi N, et al. Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression. Carbohydrate Polymers. 272: 118491. PMID 34420747 DOI: 10.1016/j.carbpol.2021.118491 |
0.121 |
|
| 2021 |
Ashrafizadeh M, Zarrabi A, Orouei S, Zabolian A, Saleki H, Azami N, Bejandi AK, Mirzaei S, Janaghard MN, Hushmandi K, Nabavi N, Baradaran B, Kumar AP, Makvandi P, Samarghandian S, et al. Interplay between SOX9 transcription factor and microRNAs in cancer. International Journal of Biological Macromolecules. PMID 33957202 DOI: 10.1016/j.ijbiomac.2021.04.185 |
0.12 |
|
| 2024 |
Ashrafizadeh M, Dai J, Torabian P, Nabavi N, Aref AR, Aljabali AAA, Tambuwala M, Zhu M. Circular RNAs in EMT-driven metastasis regulation: modulation of cancer cell plasticity, tumorigenesis and therapy resistance. Cellular and Molecular Life Sciences : Cmls. 81: 214. PMID 38733529 DOI: 10.1007/s00018-024-05236-w |
0.12 |
|
| 2024 |
Rezaee A, Rahmanian P, Nemati A, Sohrabifard F, Karimi F, Elahinia A, Ranjbarpazuki A, Lashkarbolouki R, Dezfulian S, Zandieh MA, Salimimoghadam S, Nabavi N, Rashidi M, Taheriazam A, Hashemi M, et al. NF-ĸB axis in diabetic neuropathy, cardiomyopathy and nephropathy: A roadmap from molecular intervention to therapeutic strategies. Heliyon. 10: e29871. PMID 38707342 DOI: 10.1016/j.heliyon.2024.e29871 |
0.12 |
|
| 2024 |
Hushmandi K, Einollahi B, Saadat SH, Lee EHC, Farani MR, Okina E, Huh YS, Nabavi N, Salimimoghadam S, Kumar AP. Amino acid transporters within the solute carrier superfamily: Underappreciated proteins and novel opportunities for cancer therapy. Molecular Metabolism. 84: 101952. PMID 38705513 DOI: 10.1016/j.molmet.2024.101952 |
0.12 |
|
| 2022 |
Hashemi M, Hasani S, Hajimazdarany S, Mirmazloomi SR, Makvandy S, Zabihi A, Goldoost Y, Gholinia N, Kakavand A, Tavakolpournegari A, Salimimoghadam S, Nabavi N, Zarrabi A, Taheriazam A, Entezari M, et al. Non-coding RNAs targeting notch signaling pathway in cancer: From proliferation to cancer therapy resistance. International Journal of Biological Macromolecules. 222: 1151-1167. PMID 36191781 DOI: 10.1016/j.ijbiomac.2022.09.203 |
0.113 |
|
| 2023 |
Hashemi M, Nazdari N, Gholamiyan G, Paskeh MDA, Jafari AM, Nemati F, Khodaei E, Abyari G, Behdadfar N, Raei B, Raesi R, Nabavi N, Hu P, Rashidi M, Taheriazam A, et al. EZH2 as a potential therapeutic target for gastrointestinal cancers. Pathology, Research and Practice. 253: 154988. PMID 38118215 DOI: 10.1016/j.prp.2023.154988 |
0.107 |
|
| 2023 |
Ebrahimi N, Far NP, Fakhr SS, Faghihkhorasani F, Miraghel SA, Chaleshtori SR, Rezaei-Tazangi F, Beiranvand S, Baziyar P, Manavi MS, Zarrabi A, Nabavi N, Ren J, Aref AR. The endocannabinoid system, a new gatekeeper in the pharmacology of human hepatocellular carcinoma. Environmental Research. 115914. PMID 37062475 DOI: 10.1016/j.envres.2023.115914 |
0.106 |
|
| 2020 |
Ashrafizadeh M, Hushmandi K, Rahmani Moghadam E, Zarrin V, Hosseinzadeh Kashani S, Bokaie S, Najafi M, Tavakol S, Mohammadinejad R, Nabavi N, Hsieh CL, Zarepour A, Zare EN, Zarrabi A, Makvandi P. Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer. Bioengineering (Basel, Switzerland). 7. PMID 32784981 DOI: 10.3390/bioengineering7030091 |
0.104 |
|
| 2023 |
Hashemi M, Sabouni E, Rahmanian P, Entezari M, Mojtabavi M, Raei B, Zandieh MA, Behroozaghdam M, Mirzaei S, Hushmandi K, Nabavi N, Salimimoghadam S, Ren J, Rashidi M, Raesi R, et al. Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance. Cellular & Molecular Biology Letters. 28: 33. PMID 37085753 DOI: 10.1186/s11658-023-00438-9 |
0.103 |
|
| 2023 |
Yenki P, Bhasin S, Liu L, Nabavi N, Cheng CW, Tam KJ, Peacock JW, Adomat HH, Tombe T, Fazli L, Ivanova L, Dusek C, Khosravi S, Guns EST, Wang Y, et al. Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells. Endocrine-Related Cancer. PMID 37800655 DOI: 10.1530/ERC-23-0010 |
0.103 |
|
| 2022 |
Madamsetty VS, Mohammadinejad R, Uzieliene I, Nabavi N, Dehshahri A, García-Couce J, Tavakol S, Moghassemi S, Dadashzadeh A, Makvandi P, Pardakhty A, Aghaei Afshar A, Seyfoddin A. Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems. Acs Biomaterials Science & Engineering. 8: 1763-1790. PMID 35439408 DOI: 10.1021/acsbiomaterials.2c00026 |
0.102 |
|
| 2024 |
Samaei SS, Daryab M, Gholami S, Rezaee A, Fatehi N, Roshannia R, Hashemi S, Javani N, Rahmanian P, Amani-Beni R, Zandieh MA, Nabavi N, Rashidi M, Malgard N, Hashemi M, et al. Multifunctional and stimuli-responsive liposomes in hepatocellular carcinoma diagnosis and therapy. Translational Oncology. 45: 101975. PMID 38692195 DOI: 10.1016/j.tranon.2024.101975 |
0.1 |
|
| 2020 |
Shrestha R, Nabavi N, Volik S, Anderson S, Haegert A, McConeghy B, Sar F, Brahmbhatt S, Bell R, Le Bihan S, Wang Y, Collins C, Churg A. Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma. Cancers. 12. PMID 32545767 DOI: 10.3390/cancers12061568 |
0.1 |
|
| 2021 |
Ashrafizadeh M, Zarrabi A, Mirzaei S, Hashemi F, Samarghandian S, Zabolian A, Hushmandi K, Ang HL, Sethi G, Kumar AP, Ahn KS, Nabavi N, Khan H, Makvandi P, Varma RS. Use of Gallic acid for cancer treatment: Molecular mechanisms and improvement of efficacy by nanoformulations. Food and Chemical Toxicology : An International Journal Published For the British Industrial Biological Research Association. 112576. PMID 34571052 DOI: 10.1016/j.fct.2021.112576 |
0.099 |
|
| 2018 |
Nabavi N, Wei J, Lin D, Collins CC, Gout PW, Wang Y. Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts. Frontiers in Genetics. 9: 232. PMID 30022998 DOI: 10.3389/fgene.2018.00232 |
0.093 |
|
| 2023 |
Zandieh MA, Farahani MH, Daryab M, Motahari A, Gholami S, Salmani F, Karimi F, Samaei SS, Rezaee A, Rahmanian P, Khorrami R, Salimimoghadam S, Nabavi N, Zou R, Sethi G, et al. Stimuli-responsive (nano)architectures for phytochemical delivery in cancer therapy. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 166: 115283. PMID 37567073 DOI: 10.1016/j.biopha.2023.115283 |
0.091 |
|
| 2024 |
Hashemi M, Daneii P, Asadalizadeh M, Tabari K, Matinahmadi A, Bidoki SS, Motlagh YSM, Jafari AM, Ghorbani A, Dehghanpour A, Nabavi N, Tan SC, Rashidi M, Taheriazam A, Entezari M, et al. Epigenetic regulation of hepatocellular carcinoma progression: MicroRNAs as therapeutic, diagnostic and prognostic factors. The International Journal of Biochemistry & Cell Biology. 170: 106566. PMID 38513802 DOI: 10.1016/j.biocel.2024.106566 |
0.09 |
|
| 2023 |
Hashemi M, Gholami S, Raesi R, Sarhangi S, Mahmoodieh B, Koohpar ZK, Goharrizi MASB, Behroozaghdam M, Entezari M, Salimimoghadam S, Zha W, Rashidi M, Abdi S, Taheriazam A, Nabavi N. Biological and therapeutic viewpoints towards role of miR-218 in human cancers: Revisiting molecular interactions and future clinical translations. Cellular Signalling. 110786. PMID 37380085 DOI: 10.1016/j.cellsig.2023.110786 |
0.089 |
|
| 2023 |
Karimi K, Mojtabavi S, Tehrany PM, Nejad MM, Rezaee A, Mohtashamian S, Hamedi E, Yousefi F, Salmani F, Zandieh MA, Nabavi N, Rabiee N, Ertas YN, Salimimoghadam S, Rashidi M, et al. Chitosan-based nanoscale delivery systems in hepatocellular carcinoma: Versatile bio-platform with theranostic application. International Journal of Biological Macromolecules. 242: 124935. PMID 37230442 DOI: 10.1016/j.ijbiomac.2023.124935 |
0.089 |
|
| 2023 |
Tehrany PM, Rahmanian P, Rezaee A, Ranjbarpazuki G, Sohrabi Fard F, Asadollah Salmanpour Y, Zandieh MA, Ranjbarpazuki A, Asghari S, Javani N, Nabavi N, Aref AR, Hashemi M, Rashidi M, Taheriazam A, et al. Multifunctional and theranostic hydrogels for wound healing acceleration: An emphasis on diabetic-related chronic wounds. Environmental Research. 117087. PMID 37716390 DOI: 10.1016/j.envres.2023.117087 |
0.088 |
|
| 2016 |
Kim SM, Wang Y, Nabavi N, Liu Y, Correia MA. Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame. Drug Metabolism Reviews. 1-29. PMID 27320797 DOI: 10.1080/03602532.2016.1195403 |
0.087 |
|
| 2023 |
Hashemi M, Zandieh MA, Ziaolhagh S, Mojtabavi S, Sadi FH, Koohpar ZK, Ghanbarirad M, Haghighatfard A, Behroozaghdam M, Khorrami R, Nabavi N, Ren J, Reiter RJ, Salimimoghadam S, Rashidi M, et al. Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: Therapeutic targeting, challenges and future prospective. Biochimica Et Biophysica Acta. Molecular Basis of Disease. 1869: 166714. PMID 37028606 DOI: 10.1016/j.bbadis.2023.166714 |
0.086 |
|
| 2023 |
Sadeghi MS, Sangrizeh FH, Jahani N, Abedin MS, Chaleshgari S, Ardakan AK, Baeelashaki R, Ranjbarpazuki G, Rahmanian P, Zandieh MA, Nabavi N, Aref AR, Salimimoghadam S, Rashidi M, Rezaee A, et al. Graphene oxide nanoarchitectures in cancer therapy: Drug and gene delivery, phototherapy, immunotherapy, and vaccine development. Environmental Research. 237: 117027. PMID 37659647 DOI: 10.1016/j.envres.2023.117027 |
0.084 |
|
| 2022 |
Entezari M, Ghanbarirad M, Taheriazam A, Sadrkhanloo M, Zabolian A, Goharrizi MASB, Hushmandi K, Aref AR, Ashrafizadeh M, Zarrabi A, Nabavi N, Rabiee N, Hashemi M, Samarghandian S. Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 150: 112963. PMID 35468579 DOI: 10.1016/j.biopha.2022.112963 |
0.081 |
|
| 2017 |
Lin D, Ettinger SL, Qu S, Xue H, Nabavi N, Choi SYC, Bell RH, Mo F, Haegert AM, Gout PW, Fleshner N, Gleave ME, Pollak M, Collins CC, Wang Y. Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. Oncotarget. 8: 25928-25941. PMID 28460430 DOI: 10.18632/Oncotarget.15237 |
0.079 |
|
| 2018 |
Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, et al. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience. PMID 29757368 DOI: 10.1093/Gigascience/Giy050 |
0.078 |
|
| 2016 |
Nabavi N, Bennewith KL, Churg A, Wang Y, Collins CC, Mutti L. Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. Genes & Cancer. 7: 340-354. PMID 28191281 DOI: 10.18632/Genesandcancer.124 |
0.075 |
|
| 2022 |
Ashrafizadeh M, Paskeh MDA, Mirzaei S, Gholami MH, Zarrabi A, Hashemi F, Hushmandi K, Hashemi M, Nabavi N, Crea F, Ren J, Klionsky DJ, Kumar AP, Wang Y. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. Journal of Experimental & Clinical Cancer Research : Cr. 41: 105. PMID 35317831 DOI: 10.1186/s13046-022-02293-6 |
0.075 |
|
| 2024 |
Hashem M, Mohandesi Khosroshahi E, Aliahmady M, Ghanei M, Soofi Rezaie Y, Alsadat Jafari Y, Rezaei F, Khodaparast Eskadehi R, Kia Kojoori K, Jamshidian F, Nabavi N, Rashidi M, Hasani Sadi F, Taheriazam A, Entezari M. Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism. Non-Coding Rna Research. 9: 560-582. PMID 38515791 DOI: 10.1016/j.ncrna.2024.01.009 |
0.065 |
|
| 2023 |
Hashemi M, Khosroshahi EM, Chegini MK, Abedi M, Matinahmadi A, Hosnarody YSD, Rezaei M, Saghari Y, Fattah E, Abdi S, Entezari M, Nabavi N, Rashidi M, Raesi R, Taheriazam A. miRNAs and exosomal miRNAs in lung cancer: New emerging players in tumor progression and therapy response. Pathology, Research and Practice. 251: 154906. PMID 37939448 DOI: 10.1016/j.prp.2023.154906 |
0.063 |
|
| 2022 |
Hashemi M, Mirdamadi MSA, Talebi Y, Khaniabad N, Banaei G, Daneii P, Gholami S, Ghorbani A, Tavakolpournegari A, Farsani ZM, Zarrabi A, Nabavi N, Zandieh MA, Rashidi M, Taheriazam A, et al. Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents. Pharmacological Research. 187: 106568. PMID 36423787 DOI: 10.1016/j.phrs.2022.106568 |
0.063 |
|
| 2023 |
Karimi B, Mokhtari K, Rozbahani H, Peymani M, Nabavi N, Entezari M, Rashidi M, Taheriazam A, Ghaedi K, Hashemi M. Pathological roles of miRNAs and pseudogene-derived lncRNAs in human cancers, and their comparison as prognosis/diagnosis biomarkers. Pathology, Research and Practice. 253: 155014. PMID 38128189 DOI: 10.1016/j.prp.2023.155014 |
0.059 |
|
| 2019 |
Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, Adomat HH, Lin D, Xue H, Dong X, Shukin R, Bell RH, McConeghy B, Haegert A, Brahmbhatt S, et al. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Medicine. 11: 8. PMID 30777124 DOI: 10.1186/S13073-019-0620-3 |
0.054 |
|
| 2017 |
Nabavi N, Saidy NRN, Venalainen E, Haegert A, Parolia A, Xue H, Wang Y, Wu R, Dong X, Collins C, Crea F, Wang Y. miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. Scientific Reports. 7: 4079. PMID 28642484 DOI: 10.1038/s41598-017-03731-8 |
0.05 |
|
| 2023 |
Rezaee A, Tehrany PM, Tirabadi FJ, Sanadgol N, Karimi AS, Ajdari A, Eydivandi S, Etemad S, Rajabi R, Rahmanian P, Khorrami R, Nabavi N, Aref AR, Fan X, Zou R, et al. Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 165: 115187. PMID 37499452 DOI: 10.1016/j.biopha.2023.115187 |
0.043 |
|
| 2022 |
Nann P, Nabavi N, Ziafat K, Preston R, Chau A, Krausz MR, Schwarz SKW, Maclure M. Trends in opioid dispensing after common abdominal and orthopedic surgery procedures in British Columbia: a retrospective cohort analysis. Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie. PMID 35768720 DOI: 10.1007/s12630-022-02272-7 |
0.023 |
|
| 2022 |
Mirzaei S, Gholami MH, Hushmandi K, Hashemi F, Zabolian A, Canadas I, Zarrabi A, Nabavi N, Aref AR, Crea F, Wang Y, Ashrafizadeh M, Kumar AP. Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer. Journal of Hematology & Oncology. 15: 50. PMID 35524266 DOI: 10.1186/s13045-022-01276-6 |
0.02 |
|
| 2022 |
Ziafat K, Polderman S, Nabavi N, Preston R, Chau A, Krausz MR, Schwarz SKW, Maclure M. Opioid dispensing after Cesarean delivery in British Columbia: a historical cohort analysis from 2004 to 2019. Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie. PMID 35764863 DOI: 10.1007/s12630-022-02271-8 |
0.01 |
|
| Hide low-probability matches. |